PHARMACOKINETICS OF INTRAVENOUS AND ORAL SODIUM 2-MERCAPTOETHANE SULFONATE (MESNA) IN NORMAL SUBJECTS

被引:49
作者
JAMES, CA [1 ]
MANT, TGK [1 ]
ROGERS, HJ [1 ]
机构
[1] GUYS HOSP,UNITED MED & DENT SCH,SCH MED,DIV CLIN PHARMACOL,LONDON SE1 9RT,ENGLAND
关键词
D O I
10.1111/j.1365-2125.1987.tb03092.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
引用
收藏
页码:561 / 568
页数:8
相关论文
共 20 条
[1]   THE DEVELOPMENT OF MESNA FOR REGIONAL DETOXIFICATION [J].
BROCK, N ;
POHL, J .
CANCER TREATMENT REVIEWS, 1983, 10 :33-&
[2]  
BROCK N, 1979, ARZNEIMITTEL-FORSCH, V29-1, P659
[3]   STUDIES ON THE UROTOXICITY OF OXAZAPHOSPHORINE CYTOSTATICS AND ITS PREVENTION .3. PROFILE OF ACTION OF SODIUM 2-MERCAPTOETHANE SULFONATE (MESNA) [J].
BROCK, N ;
POHL, J ;
STEKAR, J ;
SCHEEF, W .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1982, 18 (12) :1377-&
[4]   STUDIES ON THE UROTOXICITY OF OXAZAPHOSPHORINE CYTOSTATICS AND ITS PREVENTION .2. COMPARATIVE-STUDY ON THE UROPROTECTIVE EFFICACY OF THIOLS AND OTHER SULFUR-COMPOUNDS [J].
BROCK, N ;
POHL, J ;
STEKAR, J .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1981, 17 (11) :1155-1163
[5]   PHARMACOKINETICS AND MECHANISM OF ACTION OF DETOXIFYING LOW-MOLECULAR-WEIGHT THIOLS [J].
BROCK, N ;
HILGARD, P ;
POHL, J ;
ORMSTAD, K ;
ORRENIUS, S .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1984, 108 (01) :87-97
[6]  
BROCK N, 1981, EUR J CANCER CLIN ON, V17, P596
[7]   CLINICAL OVERVIEW OF MESNA [J].
BURKERT, H .
CANCER TREATMENT REVIEWS, 1983, 10 :175-181
[8]  
BURKERT H, 1984, ARZNEIMITTEL-FORSCH, V34-2, P1597
[9]   2-MERCAPTOETHANESULFONATE-CYSTEINE DISULFIDE EXCRETION FOLLOWING THE ADMINISTRATION OF 2-MERCAPTOETHANESULFONATE - A PITFALL IN THE DIAGNOSIS OF SULFITE OXIDASE DEFICIENCY [J].
DURAN, M ;
AARSEN, G ;
FOKKENS, RH ;
NIBBERING, NMM ;
CATS, BP ;
DEBREE, PK ;
WADMAN, SK .
CLINICA CHIMICA ACTA, 1981, 111 (01) :47-53
[10]   TISSUE SULFHYDRYL GROUPS [J].
ELLMAN, GL .
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1959, 82 (01) :70-77